$SVRA
Savara Inc

2022 Q3 Form 10-Q Financial Statement

#000095017022016860 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.376M $2.957M $2.354M
YoY Change -30.12% -6.22% -15.32%
% of Gross Profit
Research & Development $8.151M $6.418M $5.684M
YoY Change 24.79% -11.5% -25.1%
% of Gross Profit
Depreciation & Amortization $8.000K $8.000K $8.000K
YoY Change -80.0% -81.82% -84.0%
% of Gross Profit
Operating Expenses $10.54M $9.383M $8.046M
YoY Change 5.65% -10.23% -22.74%
Operating Profit -$10.54M -$9.383M -$8.046M
YoY Change 5.65% -10.23% -22.74%
Interest Expense $152.0K -$284.0K -$570.0K
YoY Change -126.86% -49.1% -3.88%
% of Operating Profit
Other Income/Expense, Net $149.0K $219.0K -$254.0K
YoY Change -125.96% -144.79% -228.93%
Pretax Income -$10.39M -$9.164M -$8.300M
YoY Change -1.52% -16.24% -18.79%
Income Tax
% Of Pretax Income
Net Earnings -$10.39M -$9.164M -$8.300M
YoY Change -1.52% -16.24% -18.76%
Net Earnings / Revenue
Basic Earnings Per Share -$0.07 -$0.06 -$0.05
Diluted Earnings Per Share -$0.07 -$0.06 -$54.33K
COMMON SHARES
Basic Shares Outstanding 114.0M 152.8M 114.0M
Diluted Shares Outstanding 152.8M 152.8M 152.8M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $134.1M $142.4M $151.8M
YoY Change -21.5% -21.16% -21.23%
Cash & Equivalents $119.8M $95.20M $79.20M
Short-Term Investments $14.24M $47.29M $72.57M
Other Short-Term Assets $2.131M $2.016M $1.591M
YoY Change -17.11% 48.78% 165.17%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $137.1M $145.4M $154.5M
YoY Change -21.49% -20.77% -20.67%
LONG-TERM ASSETS
Property, Plant & Equipment $59.00K $61.00K $64.00K
YoY Change -35.16% -40.2% -36.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $876.0K $952.0K $548.0K
YoY Change -16.73% -5.65% -45.2%
Total Long-Term Assets $10.69M $11.39M $11.67M
YoY Change -15.77% -12.0% -8.81%
TOTAL ASSETS
Total Short-Term Assets $137.1M $145.4M $154.5M
Total Long-Term Assets $10.69M $11.39M $11.67M
Total Assets $147.8M $156.8M $166.2M
YoY Change -21.1% -20.19% -19.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $893.0K $805.0K $1.296M
YoY Change -30.18% -62.45% -52.0%
Accrued Expenses $4.270M $2.901M $2.527M
YoY Change -18.12% -16.9% -43.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $12.50M
YoY Change -100.0%
Total Short-Term Liabilities $5.163M $3.706M $16.32M
YoY Change -51.57% -34.23% 126.49%
LONG-TERM LIABILITIES
Long-Term Debt $26.01M $25.94M $13.31M
YoY Change 21.83% 2.21% -47.28%
Other Long-Term Liabilities $71.00K $87.00K $102.0K
YoY Change 108.82% 148.57% 75.86%
Total Long-Term Liabilities $26.08M $26.03M $13.41M
YoY Change 21.97% 2.55% -47.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.163M $3.706M $16.32M
Total Long-Term Liabilities $26.08M $26.03M $13.41M
Total Liabilities $31.24M $29.74M $29.73M
YoY Change -2.5% -4.24% -8.54%
SHAREHOLDERS EQUITY
Retained Earnings -$328.4M -$318.0M -$308.8M
YoY Change 13.55% 14.1% 15.35%
Common Stock $446.5M $446.0M $445.6M
YoY Change 0.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $116.5M $127.0M $136.5M
YoY Change
Total Liabilities & Shareholders Equity $147.8M $156.8M $166.2M
YoY Change -21.1% -20.19% -19.94%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$10.39M -$9.164M -$8.300M
YoY Change -1.52% -16.24% -18.76%
Depreciation, Depletion And Amortization $8.000K $8.000K $8.000K
YoY Change -80.0% -81.82% -84.0%
Cash From Operating Activities -$8.162M -$9.316M -$8.400M
YoY Change -8.57% -23.58% -12.47%
INVESTING ACTIVITIES
Capital Expenditures -$4.000K -$5.000K
YoY Change -63.64% -16.67%
Acquisitions
YoY Change
Other Investing Activities $33.00M $25.20M $53.67M
YoY Change 153.96% -835.77% -169.03%
Cash From Investing Activities $33.00M $25.20M $53.67M
YoY Change 154.15% -834.33% -169.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.000K 88.00K -1.000K
YoY Change -110.0% -72.5% -100.0%
NET CHANGE
Cash From Operating Activities -8.162M -9.316M -8.400M
Cash From Investing Activities 33.00M 25.20M 53.67M
Cash From Financing Activities -1.000K 88.00K -1.000K
Net Change In Cash 24.83M 15.97M 45.22M
YoY Change 510.75% -204.35% 36.59%
FREE CASH FLOW
Cash From Operating Activities -$8.162M -$9.316M -$8.400M
Capital Expenditures -$4.000K -$5.000K
Free Cash Flow -$8.158M -$9.311M
YoY Change -8.5% -23.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001160308
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32157
dei Entity Registrant Name
EntityRegistrantName
Savara Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1318182
dei Entity Address Address Line1
EntityAddressAddressLine1
6836 Bee Cave Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Building III
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 201
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78746
dei City Area Code
CityAreaCode
512
dei Local Phone Number
LocalPhoneNumber
614-1848
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
SVRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
114042642
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95153000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34012000
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
47286000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
127159000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2946000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3829000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
145385000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
165000000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73000
CY2022Q2 svra In Process Research And Development
InProcessResearchAndDevelopment
10379000
CY2021Q4 svra In Process Research And Development
InProcessResearchAndDevelopment
11274000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
952000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
251000
CY2022Q2 us-gaap Assets
Assets
156777000
CY2021Q4 us-gaap Assets
Assets
176598000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
805000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1443000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2901000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4884000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
8333000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3706000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14660000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25942000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
17323000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
87000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
117000
CY2022Q2 us-gaap Liabilities
Liabilities
29735000
CY2021Q4 us-gaap Liabilities
Liabilities
32100000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
114041271
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
114041271
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
114036892
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
114036892
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
116000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
116000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
445927000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
444898000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1016000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-317985000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-300521000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
127042000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
144498000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
156777000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
176598000
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6418000
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7252000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
12102000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
14841000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2957000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3153000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5311000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5931000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8000
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
47000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
16000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
94000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
9383000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
10452000
us-gaap Operating Expenses
OperatingExpenses
17429000
us-gaap Operating Expenses
OperatingExpenses
20866000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9383000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10452000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17429000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20866000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-284000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-558000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-854000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1150000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
42000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
43000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
29000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-15000
CY2022Q2 svra Tax Credit Income
TaxCreditIncome
461000
CY2021Q2 svra Tax Credit Income
TaxCreditIncome
26000
svra Tax Credit Income
TaxCreditIncome
790000
svra Tax Credit Income
TaxCreditIncome
873000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
219000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-489000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-35000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-292000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9164000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10941000
us-gaap Net Income Loss
NetIncomeLoss
-17464000
us-gaap Net Income Loss
NetIncomeLoss
-21158000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152771103
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152771103
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152460531
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152460531
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152770434
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152770434
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114934938
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114934938
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-745000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
83000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-953000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-348000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
24000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-68000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9889000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10834000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18485000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21508000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
144498000
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
574000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-208000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-88000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-8300000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
136475000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
456000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-745000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9164000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
127042000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
64383000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
121827000
CY2021Q1 svra Adjustment To Additional Paid In Capital Repurchase Of Pre Funded Warrants
AdjustmentToAdditionalPaidInCapitalRepurchaseOfPreFundedWarrants
3909000
CY2021Q1 svra Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
2546000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
946000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-431000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-26000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-10217000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
175121000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
321000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
771000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
83000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
24000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10941000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
165382000
us-gaap Profit Loss
ProfitLoss
-17464000
us-gaap Profit Loss
ProfitLoss
-21158000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
16000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
94000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
66000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
116000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
29000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-15000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
198000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
277000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-371000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-668000
us-gaap Share Based Compensation
ShareBasedCompensation
1030000
us-gaap Share Based Compensation
ShareBasedCompensation
1717000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1337000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
170000
svra Increase Decrease In Noncurrent Assets
IncreaseDecreaseInNoncurrentAssets
803000
svra Increase Decrease In Noncurrent Assets
IncreaseDecreaseInNoncurrentAssets
890000
svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
-2463000
svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
-2413000
svra Increase Decrease In Long Term Liabilities
IncreaseDecreaseInLongTermLiabilities
-47000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17741000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21791000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
16004000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
114445000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
83593000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
33280000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
11276000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
78860000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-81171000
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
3909000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
26350000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
26438000
svra Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
122148000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
svra Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants Net
ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrantsNet
2546000
svra Repurchase Of Shares For Minimum Tax Withholdings
RepurchaseOfSharesForMinimumTaxWithholdings
1000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
87000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
120790000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-65000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-55000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
61141000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17773000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34012000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22880000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95153000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
40653000
us-gaap Interest Paid Net
InterestPaidNet
857000
us-gaap Interest Paid Net
InterestPaidNet
974000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-318000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17700000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95200000
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
47300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Management’s estimates include, but are not limited to, those related to the accrual of research and development expenses and general and administrative costs, certain financial instruments recorded at fair value, the valuation of stock-based compensation, and the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, changes in circumstance and facts, and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Accordingly, actual results could be materially different from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2022Q2 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
771000
CY2021Q4 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
838000
CY2022Q2 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
159000
CY2021Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
306000
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
260000
CY2022Q2 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
1145000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents. The Company places its cash and cash equivalents with a limited number of high-quality financial institutions and at times may exceed the amount of insurance provided on such deposits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2021Q4 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
1623000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1143000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2526000
CY2022Q2 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
513000
CY2021Q4 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
600000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q2 svra Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
1578000
CY2021Q4 svra Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
1902000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
427000
CY2022Q2 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
178000
CY2021Q4 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
356000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2946000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3829000
CY2022Q2 svra Accrued Lease Liability
AccruedLeaseLiability
100000
CY2021Q4 svra Accrued Lease Liability
AccruedLeaseLiability
135000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2901000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4884000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
47403000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
117000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
47286000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
127206000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
47000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
127159000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
8333000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
18167000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
17667000
CY2022Q2 svra Long Term Debt Maturities Repayments Of Principal In Year Six
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix
9562000
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
27229000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
26500000
CY2022Q2 svra Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
704000
CY2021Q4 svra Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
694000
CY2022Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
535000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25942000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
17323000
svra Increase Decrease In Process Research And Development Due To Foreign Currency Translation
IncreaseDecreaseInProcessResearchAndDevelopmentDueToForeignCurrencyTranslation
-900000
svra Increase Decrease In Process Research And Development Due To Foreign Currency Translation
IncreaseDecreaseInProcessResearchAndDevelopmentDueToForeignCurrencyTranslation
-400000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
85000
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
48000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
65000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
25942000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
25656000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
8333000
CY2021Q1 svra Proceeds From Issuance Of Common Stock And Pre Funded Warrants
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants
129968000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
7737000
CY2021Q1 svra Net Proceeds After Deducting Underwriting Discounts Commissions And Offering Expenses
NetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpenses
122231000
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
46014655
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
46299718
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
38808502
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
942000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-937000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1021000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1016000
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
3121000
CY2022Q2 svra Contingent Milestones Commitments Recognized
ContingentMilestonesCommitmentsRecognized
0
CY2021Q1 svra Estimated Parexel Service Fees And Pass Through Expenses And Investigator Fees
EstimatedParexelServiceFeesAndPassThroughExpensesAndInvestigatorFees
33000000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6218841
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
95000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
249563
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6064278
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1272375
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
5500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
125000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1141875
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152770434
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114934938
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114934938
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
456000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
771000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1030000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1717000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7283946
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9034906
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9164000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10941000
us-gaap Net Income Loss
NetIncomeLoss
-17464000
us-gaap Net Income Loss
NetIncomeLoss
-21158000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9164000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10941000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17464000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21158000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9164000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10941000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17464000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21158000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152771103
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152771103
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152460531
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152460531
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152770434
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18

Files In Submission

Name View Source Status
R48.htm Edgar Link pending
0000950170-22-016860-index-headers.html Edgar Link pending
0000950170-22-016860-index.html Edgar Link pending
0000950170-22-016860.txt Edgar Link pending
0000950170-22-016860-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img197167228_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
svra-20220630.htm Edgar Link pending
svra-20220630.xsd Edgar Link pending
svra-ex31_1.htm Edgar Link pending
svra-ex31_2.htm Edgar Link pending
svra-ex32_1.htm Edgar Link pending
svra-20220630_cal.xml Edgar Link unprocessable
svra-20220630_pre.xml Edgar Link unprocessable
svra-20220630_lab.xml Edgar Link unprocessable
svra-20220630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
svra-20220630_def.xml Edgar Link unprocessable